Sign In
Buy ALDX
$1.86
+0.220 (+13.41%)
At Close: Jun 03, 2026
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q1 2021 Results - Earnings Call Transcript
02:27pm, Thursday, 06'th May 2021
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q1 2021 Results - Earnings Call Transcript
Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
06:31pm, Wednesday, 28'th Apr 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to impro
Why Aldeyra Therapeutics Stock Is Sinking Today
12:53pm, Wednesday, 28'th Apr 2021
The company plans to conduct a public stock offering.
Aldeyra Seeks To Raise $125M Via Equity To Support Reproxalap US Application
06:10am, Wednesday, 28'th Apr 2021
Aldeyra Therapeutics Inc (NASDAQ: ALDX) intends to sell $125 million shares of its common stock in an underwritten public offering. Underwriters will have an option to purchase up to an addition
Why Aldeyra Therapeutics Stock Is Soaring Today
11:06am, Tuesday, 27'th Apr 2021
The company reported great clinical results for its lead pipeline candidate.
ALDX Stock: Over 25% Increase Pre-Market Explanation
07:57am, Tuesday, 27'th Apr 2021
The stock price of Aldeyra Therapeutics Inc (NASDAQ: ALDX) increased by over 25% pre-market. This is why it happened.
Aldeyra Therapeutics Stock Is Trading Higher On Acing Allergic Conjunctivitis Study With Reproxalap
07:40am, Tuesday, 27'th Apr 2021
Aldeyra Therapeutics Inc (NASDAQ: ALDX) has announced positive top-line results from the Phase 3 INVIGORATE trial evaluating 0.25% reproxalap, in patients with allergic conjunctivitis. The 95-su
Strong Reproxalap Results Give Aldeyra A Good Balance Of Risk Versus Potential Reward
04:55pm, Tuesday, 16'th Mar 2021
Aldeyra's lead therapy reproxalap recently had positive Phase 3 results announced.
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q4 2020 Results - Earnings Call Transcript
02:33pm, Thursday, 11'th Mar 2021
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q4 2020 Results - Earnings Call Transcript
Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights
07:00am, Thursday, 11'th Mar 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to impro
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
08:00am, Tuesday, 02'nd Mar 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will participate in analyst
Aldeyra Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
08:00am, Thursday, 18'th Feb 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will present at the 10th
Aldeyra Therapeutics Deserves A Shout Out
06:16am, Sunday, 14'th Feb 2021
Today, we are going to take an in-depth look at an ocular concern named Aldeyra Therapeutics. Shortly after positive results from the run-in cohort of a pivotal trial evaluating its lead candidate (re
Aldeyra: Reproxalap's Phase 3 Clinical Results, Expected ~75% Sales CAGR, And More
07:53pm, Monday, 18'th Jan 2021
Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company aiming to develop novel therapies for immune-mediated diseases with its lead candidate Reproxalap finishing up its Phase 3 multi-tr
3 Biotech Stocks That Jumped Last Week
09:59am, Sunday, 17'th Jan 2021
Find out what led to the biotech industry's biggest gains.
